Nov

Nov Stock-Based Compensation

The Stock-Based Compensation (SBC) of Nov (NOV) as of Nov 3, 2026 is 67.00 M USD. In the previous year, Stock-Based Compensation (SBC) was 70.00 M USD — a change of -4.29% (lower).

Stock-Based Compensation

67.00 MUSD

YoY

-4.29%

Last updated:

Stock-Based Compensation (SBC) of Nov is 2025 67.00 M USD. Stock-Based Compensation (SBC) of Nov was 2024 70.00 M USD. It decreases by -4.29% lower compared to the previous year.

The Nov Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
110.00 M USD
Jan 1, 2019
130.00 M USD
Jan 1, 2020
105.00 M USD
Jan 1, 2021
78.00 M USD
Jan 1, 2022
67.00 M USD
Jan 1, 2023
66.00 M USD
Jan 1, 2024
70.00 M USD
Jan 1, 2025
67.00 M USD
The Nov Stock-Based Compensation history
YEARStock-Based CompensationYoY
67.00 MUSD-4.29%
70.00 MUSD+6.06%
66.00 MUSD-1.49%
67.00 MUSD-14.10%
78.00 MUSD-25.71%
105.00 MUSD-19.23%
130.00 MUSD+18.18%
110.00 MUSD-11.29%
124.00 MUSD+15.89%
107.00 MUSD-1.83%
109.00 MUSD+7.92%
101.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nov Stock analysis

What does Nov do? Nov Inc is a globally operating company that was founded in the USA in 1976. The company specializes in the development and manufacture of products in various fields, including pharmaceuticals, biotechnology, agrochemicals, and electronics. Nov Inc's business model is based on the research and development of new technologies and products. The company invests a significant portion of its resources in the research and development of new drugs and technologies. Nov Inc works closely with scientific organizations and universities to achieve this. The goal of Nov Inc is to develop products that have a positive impact on health, science, and the environment. The company aims to improve the quality of life for people worldwide by developing innovative products that meet the needs of its customers. Nov Inc is divided into several divisions. The main divisions are pharmaceuticals, biotechnology, diagnostics, crop protection, and electronics. In each of these divisions, the company produces products tailored to the needs of its customers. In the pharmaceutical field, Nov Inc develops and produces drugs for the treatment of various diseases such as cancer, diabetes, and cardiovascular diseases. Nov Inc's products are well-known worldwide and are taken by millions of patients every day. The company is proud to make a significant contribution to improving the health of people worldwide. In the biotechnology division, Nov Inc develops products for use in agriculture and environmental protection. This includes improved seed varieties that are more resistant to insects and diseases, thus reducing the use of pesticides. Nov Inc also produces biological pesticides that protect plants from pests while being non-toxic and environmentally friendly. In the diagnostics division, Nov Inc develops and produces tests for the diagnosis of infectious diseases and other medical conditions. These tests are important for the timely detection of diseases and enable early treatment. In the electronics division, Nov Inc develops and produces electronic devices and components. This includes semiconductors, sensors, and displays. These components are used in various industries, including telecommunications, automotive, and aerospace. In addition to the above-mentioned divisions, Nov Inc also offers other products, including food additives, colorants, fragrances, and chemicals for industrial use. Overall, Nov Inc has made a significant contribution to improving health, science, and the environment over the past decades. The company is globally recognized for its innovative products and technologies and will remain an important player in research and development in the future. Nov is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nov stock

Stock-Based Compensation (SBC) of Nov is 67.00 M USD in 2025.

Stock-Based Compensation (SBC) of Nov changed from 70.00 M USD to 67.00 M USD, representing a -4.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Nov since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Nov historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nov

All Key Metrics — Nov